Treatment of Glanzmann's Thrombasthenia: A Prospective Observational Registry

Trial Profile

Treatment of Glanzmann's Thrombasthenia: A Prospective Observational Registry

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jan 2015

At a glance

  • Drugs Eptacog alfa (Primary)
  • Indications Thrombasthenia
  • Focus Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jul 2014 According to a Novo Nordisk media release, eptacog alfa (NovoSeven RT) was approved by the US FDA for the perioperative management and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.
    • 13 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top